The Best Peptide for Insulin Resistance & Mitochondrial Health: MOTS-C Masterclass
A 13-minute solo explainer in which Thomas DeLauer walks through preclinical and limited human findings on MOTS-C, an exercise-linked mitochondrial peptide, covering insulin sensitivity, performance, muscle and longevity.
Key moments
Tap a moment to play the video from there.
- 0:00Disclaimer and why MOTS-CDeLauer says the video is for entertainment, that the evidence is mostly preclinical, and that people should consult a doctor. He introduces MOTS-C as an exercise-linked peptide made by the mitochondria.
- 1:17Book and supplement plugHe promotes a friend's book on nutrient deficiencies and a related supplement, with links in the description. This section is not about MOTS-C.
- 2:28Human exercise biopsy studyHe describes a study in which sedentary people did light exercise for about 4 hours. Muscle biopsies showed a 12-fold increase in MOTS-C afterward.
- 5:08Insulin resistance and inflammation findingsDeLauer reports preclinical results on a high fat diet: no insulin resistance in treated animals, less appetite, weight loss and lower inflammatory markers. He says the effect was strongest in muscle.
- 6:02Proposed mechanism via AMPKHe says MOTS-C is thought to alter the folate cycle and purine synthesis, raising AMPK. In his telling this makes the body behave as if it were exercising.
- 6:55Treadmill and coordination resultsHe cites a preclinical study where coordination improved and treadmill performance rose at 10 days but not 7. All treated animals reached a full sprint against 16.6 percent of controls.
- 8:55Myostatin and muscle protectionDeLauer cites a preclinical study reporting a 40 percent reduction in myostatin and protection from obesity-related muscle atrophy. He contrasts this with follistatin gene therapies.
- 10:42Age decline and longevity dataHe says people aged 70 to 80 showed a 21 percent lower exercise-induced MOTS-C response than people aged 18 to 30. He also cites a mitochondrial variant proposed to help explain Japanese longevity.
- 12:15Late-life dosing and healthspanHe describes a preclinical study of late-life dosing three times per week with a clear healthspan gain and a modest 7 percent lifespan gain. He warns that animal lifespan results may not translate to people.
What the video says
Thomas DeLauer presents MOTS-C as a peptide encoded in mitochondrial DNA and released during exercise, which he describes as something like a concentrated exercise mimetic. He opens with a disclaimer that the video is for entertainment, that most of the evidence is preclinical, and that clinical data are lacking. He tells viewers to talk to a doctor about any peptide use. A short section in the first few minutes promotes a book and a supplement from a friend.
He then works through several studies. In a human experiment he describes, sedentary people did about four hours of light exercise and muscle biopsies showed a 12-fold rise in MOTS-C afterward. In preclinical work on a very high fat diet, DeLauer says animals given MOTS-C did not develop the insulin resistance seen in controls. He also reports weight loss, lower appetite, better glucose handling, and lower IL-6 and TNF-alpha. He says the effect was larger in muscle than in other tissues, and that older animals with insulin resistance came to resemble younger ones.
DeLauer gives a proposed mechanism: MOTS-C alters the folate cycle and purine synthesis, which raises AMPK, the body's energy sensor, and so mimics some effects of exercise. He then covers performance results from preclinical studies. Motor coordination improved, treadmill performance rose after 10 days of dosing but not 7, and all treated animals reached a full sprint against 16.6 percent of controls. On muscle, he cites a 40 percent drop in myostatin and protection against obesity-related muscle loss.
The last section is about longevity. DeLauer cites a study reporting a 21 percent lower exercise-induced MOTS-C response in people aged 70 to 80 than in people aged 18 to 30. He also cites a paper linking a mitochondrial DNA variant common in Japanese populations to longevity. A preclinical study of late-life dosing found a clear gain in healthspan and a modest 7 percent gain in lifespan. He cautions that lifespan gains in animals may not carry over to people.
On each compound
MOTS-c0:31
DeLauer describes MOTS-C as a peptide encoded by mitochondrial DNA and released with exercise. He cites preclinical and limited human data on insulin sensitivity, performance, muscle and healthspan, and says clinical trials are lacking.
See how your DNA reads MOTS-c“So in an interesting way it's like a concentrated exercise mimetic.”
What this video doesn’t settle
- The performance, muscle and insulin findings come from preclinical studies, and the video does not show they hold in people taking MOTS-C as a supplement.
- The only human data described measure natural MOTS-C release after exercise, not the effects of giving the peptide.
- No doses, safety data, side effects or human dosing protocols are given, although DeLauer says the safety profile looks realistic.
Questions this video answers
What is MOTS-C according to Thomas DeLauer?
DeLauer describes it as a peptide encoded by the mitochondria and produced in response to exercise. He calls it something like a concentrated exercise mimetic.
How does MOTS-C change with exercise and age?
DeLauer cites a human study in which muscle biopsies showed a 12-fold rise in MOTS-C after light exercise. He also cites a study reporting about a 21 percent lower exercise response in people aged 70 to 80 than in people aged 18 to 30.
How does MOTS-C work in the body, according to this video?
DeLauer says it is thought to alter the folate cycle and purine synthesis, which raises AMPK, the body's energy sensor. He says this improves mitochondrial function and density in a way that resembles exercise.
What does the video say about MOTS-C research quality?
DeLauer states that most of the findings come from preclinical studies, with some human data and a lack of clinical trials. He says the video is for entertainment and tells viewers to talk to a doctor.
Video by Thomas DeLauer on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
